Beam Therapeutics
Beam Therapeutics (NASDAQ: BEAM) is a publicly traded Gene & Genome Editing Platforms company founded in 2017 and based in Cambridge, United States.
Founded in 2017 in Cambridge, Massachusetts by gene-editing pioneers David Liu, Feng Zhang, and Keith Joung, Beam Therapeutics was the first company built around CRISPR base editing — chemistry developed in Liu's lab that converts one DNA base into another at a target site without cutting both strands of the double helix. Avoiding double-strand breaks reduces the risk of unwanted insertions, deletions, and chromosomal rearrangements. Beam's platform spans multiple DNA base editors and an RNA base editor derived from Zhang's lab. The company raised $180M in its 2020 IPO and trades on Nasdaq as BEAM.
It commercialized base editing, the first widely used precision alternative to break-and-repair CRISPR.
beamtx.com ↗·Gene & Genome Editing Platforms·
United States·public · NASDAQ: BEAM 
